Repare Therapeutics Inc. has announced new amendments to the severance benefits for certain company officers, including Executive Vice President and Chief Scientific Officer, Dr. Michael Zinda. Approved by the Board's Compensation Committee, the revised terms entitle Dr. Zinda to a lump sum payment equal to nine months of his current base salary if his employment is terminated without cause or if he resigns for good reason, not in connection with a change in control. Additionally, Repare will cover Dr. Zinda's COBRA health insurance premiums for up to 12 months following his departure. The agreement also provides for nine months of accelerated vesting of his unvested equity awards and a pro-rated target bonus for the period served during the year of separation. If a change in control occurs within 90 days post-separation, Dr. Zinda will receive additional severance benefits as outlined in his employment agreement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.